| Cauldron Energy Limited (CXU) ORDINARY FULLY PAID |
Energy |
$59 |
Change of Director's Interest Notice - Wells
|
7 Jan 2026 9:59AM |
$0.024 |
$0.029 |
risen by
20.83%
|
|
| Kalamazoo Resources Limited (KZR) ORDINARY FULLY PAID |
Materials |
$49 |
Cleansing Notice
|
7 Jan 2026 9:55AM |
$0.205 |
$0.155 |
fallen by
24.39%
|
|
| Kalamazoo Resources Limited (KZR) ORDINARY FULLY PAID |
Materials |
$49 |
Application for quotation of securities - KZR
|
7 Jan 2026 9:54AM |
$0.205 |
$0.155 |
fallen by
24.39%
|
|
| Trek Metals Limited (TKM) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$124 |
Change of Director's Interest Notice
|
7 Jan 2026 9:54AM |
$0.070 |
$0.200 |
risen by
185.71%
|
|
| Unico Silver Limited (USL) ORDINARY FULLY PAID |
Materials |
$494 |
La Negra SE Delivers Exceptional Drill Results
|
7 Jan 2026 9:54AM |
$0.905 |
$0.785 |
fallen by
13.26%
|
|
USL - Price-sensitive ASX Announcement
Full Release
Key Points
- USL reports exceptional drill results at La Negra SE, Joaquin Project.
- Drilling reveals 850m strike, 175m vertical extent of mineralisation.
- Significant drill result: JDD113-25 with 107m at 165gpt AgEq from 18m.
- Drilling nears completion, supports high confidence Indicated Resource.
- Company plans to move to Pre-Feasibility Study.
- Regional exploration suggests potential for further discoveries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$39,804 |
Statement of Changes in Beneficial Ownership
|
7 Jan 2026 9:53AM |
$101.580 |
$70.580 |
fallen by
30.52%
|
|
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$37 |
CVB Notified of China ODI Approval for Strategic Investment
|
7 Jan 2026 9:53AM |
$0.075 |
$0.078 |
risen by
4%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- CurveBeam AI receives China ODI approval for investment.
- Investment from Shandong WeiYing part of a larger A$10 million deal.
- Initial A$4 million tranche to be received in January 2026.
- 10-year agreement covers commercialization in Greater China.
- Supported by WEGO Orthopaedics, a major Chinese orthopaedic supplier.
- Funds to enhance regulatory, manufacturing, and commercial activities.
- Shares issued at A$0.405 per share, a premium over market price.
- Investment strengthens financial position and global growth strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$39,804 |
Statement of Changes in Beneficial Ownership
|
7 Jan 2026 9:52AM |
$101.580 |
$70.580 |
fallen by
30.52%
|
|
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$39,804 |
Statement of Changes in Beneficial Ownership
|
7 Jan 2026 9:52AM |
$101.580 |
$70.580 |
fallen by
30.52%
|
|
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$39,804 |
Statement of Changes in Beneficial Ownership
|
7 Jan 2026 9:51AM |
$101.580 |
$70.580 |
fallen by
30.52%
|
|
| Turaco Gold Limited (TCG) ORDINARY FULLY PAID |
Materials |
$692 |
Anuiri Resource Drilling Shows MRE Growth
|
7 Jan 2026 9:51AM |
$0.805 |
$0.658 |
fallen by
18.32%
|
|
TCG - Price-sensitive ASX Announcement
Full Release
Key Points
- Mineralisation at both Anuiri and Jonction deposits remains open in all directions.
- The MRE for Anuiri and Jonction will be updated as part of the ongoing PFS for the Afema Project.
- Recent drilling results at Anuiri confirmed previous resource modeling and indicate modest MRE growth.
- Exploration drilling continues at new targets including Adiopan, Baffia, Kotoka, and Affienou.
- The Afema Project holds a current MRE of 4.1 million ounces of gold.
- Drilling results are expected soon from the Adiopan prospect.
- Metallurgical testwork is part of the PFS efforts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$39,804 |
Statement of Changes in Beneficial Ownership
|
7 Jan 2026 9:50AM |
$101.580 |
$70.580 |
fallen by
30.52%
|
|
| SQX Resources Limited (SQX) ORDINARY FULLY PAID |
Materials |
$12 |
Section 708A Cleansing Statement
|
7 Jan 2026 9:50AM |
$0.140 |
$0.170 |
risen by
21.43%
|
|
| Peppermint Innovation Limited (PIL) ORDINARY FULLY PAID |
Information Technology |
$10 |
Suspension from Quotation
|
7 Jan 2026 9:48AM |
$0.004 |
$0.004 |
fallen by
0%
|
|
| Marquee Resources Limited (MQR) ORDINARY FULLY PAID |
Materials |
$7 |
Phase 2 drilling delivers high-grade antimony at Mt Clement
|
7 Jan 2026 9:47AM |
$0.009 |
$0.009 |
fallen by
0%
|
|
MQR - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 2 RC drilling at Mt Clement totaled 2,908 meters across 14 holes.
- Significant antimony mineralization was confirmed in all reported holes.
- Three mineralized zones identified: Taipan, Dugite, and Gwardar.
- High-grade antimony, silver, and lead intersections were achieved.
- Drilling results support further exploration and development strategies.
- Metallurgical test work has begun to refine production scenarios.
- An updated JORC Mineral Resource Estimate is planned.
- Phase 3 drilling is anticipated to begin in Q1 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Flynn Gold Limited (FG1) ORDINARY FULLY PAID |
Materials |
$15 |
Change in substantial holding
|
7 Jan 2026 9:46AM |
$0.026 |
$0.025 |
fallen by
1.96%
|
|
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,131 |
UC San Diego Health adopts CTVQ
|
7 Jan 2026 9:45AM |
$4.190 |
$3.740 |
fallen by
10.74%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- UC San Diego Health has commenced clinical use of 4DMedical's CT:VQâ„¢ system.
- UC San Diego Health is the fourth U.S. academic medical centre to adopt CT:VQâ„¢, following Stanford, University of Miami, and Cleveland Clinic.
- The arrangement provides introductory pricing until March 2026 before transitioning to full commercial terms.
- CT:VQâ„¢ eliminates the need for radioisotopes and contrast administration, offering superior image resolution.
- Dr. Jonathan Chung leads the adoption at UC San Diego, enhancing the institution's imaging capabilities.
- 4DMedical's rapid deployment of CT:VQâ„¢ at prestigious institutions supports their commercialisation strategy.
- 4DMedical is a global leader in respiratory imaging technology, leveraging advanced AI capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Santana Minerals Limited (SMI) ORDINARY FULLY PAID |
Materials |
$741 |
Step-out drilling unlocks major new extension north of RAS
|
7 Jan 2026 9:45AM |
$0.910 |
$0.885 |
fallen by
2.75%
|
|
| SQX Resources Limited (SQX) ORDINARY FULLY PAID |
Materials |
$12 |
Notification regarding unquoted securities - SQX
|
7 Jan 2026 9:45AM |
$0.140 |
$0.170 |
risen by
21.43%
|
|
| SQX Resources Limited (SQX) ORDINARY FULLY PAID |
Materials |
$12 |
Application for quotation of securities - SQX
|
7 Jan 2026 9:45AM |
$0.140 |
$0.170 |
risen by
21.43%
|
|
| Island Pharmaceuticals Limited (ILA) ORDINARY FULLY PAID |
Health Care |
$100 |
US Patent Granted for Galidesivir in filoviridae viruses
|
7 Jan 2026 9:44AM |
$0.410 |
$0.370 |
fallen by
9.76%
|
|
ILA - Price-sensitive ASX Announcement
Full Release
Key Points
- US Patent Number 12,508,266 granted for the use of Galidesivir in treating filoviridae viruses.
- Patent protection is provided through October 2031.
- This patent includes claims for treating viruses like Marburg and Ebola.
- The patent aligns with Island Pharmaceuticals' clinical development strategy for Galidesivir.
- Galidesivir is an antiviral molecule with broad-spectrum activity against over 20 RNA viruses.
- Filoviridae viruses are classified as biological select agents posing severe public health risks.
- Island Pharmaceuticals focuses on drugs addressing urgent viral diseases and biosecurity threats.
- The patent is part of a broader strategy to expand Island Pharmaceuticals' intellectual property.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vmoto Limited (VMT) ORDINARY FULLY PAID |
Consumer Discretionary |
$27 |
Change of Director's Interest Notice x 2
|
7 Jan 2026 9:44AM |
$0.072 |
$0.069 |
fallen by
4.17%
|
|
| VanEck Australian Corporate Bond Plus ETF (PLUS) |
Financials |
$395 |
Final Dividend/Distribution for period ending 7 Jan 2026
|
7 Jan 2026 9:44AM |
$16.960 |
$17.000 |
risen by
0.24%
|
|
| VanEck 1-5 Year Australian Government Bond ETF (1GOV) |
Financials |
$26 |
Final Dividend/Distribution for period ending 7 Jan 2026
|
7 Jan 2026 9:44AM |
$51.400 |
$51.370 |
fallen by
0.06%
|
|
| VanEck 5-10 Year Australian Government Bond ETF (5GOV) |
Financials |
$88 |
Final Dividend/Distribution for period ending 7 Jan 2026
|
7 Jan 2026 9:44AM |
$51.800 |
$52.135 |
risen by
0.65%
|
|